Huang Lequn: Science entrepreneur's second venture.

Guide: Whoever has mastered the policy seizes the opportunity.
was admitted to the Department of Chemistry of Nanjing University in 1977, becoming the first batch of college students after the resumption of the college entrance examination, and was admitted to the Department of Chemistry of the University of Iowa in the United States, becoming the first batch of graduate students sent by the State of China after the reform and opening up; After studying for and obtaining his Ph.D. in Chemistry at Iowa State University, he was hired as Director and Senior Research Fellow of the Center for Pharmaceutical Research Technology at Bayer Pharmaceutical America Research Center, a world-renowned multinational company, becoming the first Chinese-American to enter the Center; In the same year, Dongying (Jiangsu) Pharmaceutical Co., Ltd. was founded, in 2013 Dongying (Jiangsu) Pharmaceutical Co., Ltd. was acquired by Shanghai Pharmaceutical Group at a valuation of 778 million, the company's core products anaesthetic muscular muscular injection with benzodiaxane aquco ammonium to fill the gap in the shanghai Pharmaceutical Group in the anaesthetic muscle pine product line.
the same year, Jiangsu Jiayi Pharmaceutical Co., Ltd., focusing on the field of high-end generic drugs.
strive to become China's premier high-end generics company within 5-10 years.
Huang Lequn, a long time ago, Jiangsu Jiayi Pharmaceuticals is the second enterprise he founded.
6 a.m., Huang Lequn will run for an hour in the morning, and then go to the office to listen to the department head report work, basically every day.
consistent evaluation, a variety simply do BE test no less than five million.
Jiayi medicine has four varieties into the BE stage, so, Jiangsu walked in the forefront of the country, Jiayi medicine has been in front of Jiangsu.
2016, Jiayi Pharmaceuticals has invested tens of millions of yuan in bioethic research and clinical base construction.
However, "consistency evaluation, however, the product will die, this input is only to solve the problem of enterprise survival, according to the high requirements of consistency evaluation to do a good job of the effective equivalent research of new varieties, and sustainable development is the direction."
" Huang Lequn judged that high-end generic drugs (me too) and new dosage form innovative drugs (me better) are the most promising in China at present, in which dosage form innovation is much more likely to succeed than structural innovation, but also solve the actual problems of patients.
, me too and me better are important paths for the development of Jiayi Pharmaceuticals.
path is original drugs, including no-market or brand-new target drugs worldwide," said Mr.
" Huang Lequn is full of confidence.
large-handed investment to do the most popular BE clinical research, founded more than three years, Jiayi Pharmaceutical has been in the forefront of the national counterparts, has now obtained more than 20 clinical approvals, Huang Lequn hope they can be listed.
under the tide of China's drug reform, Huang Said he was willing to accept the challenge and take risks.
" he called "the road."
"road trip" is what Huang Lequn has been doing all his life.
Huang Lequn is the first college graduates to resume the college entrance examination, the first batch to study in the United States to study for a Ph.D., the first batch to get the United States outstanding talent green card, but also the first to return home to start a business.
these experiences gave Huang Lequn a concept, although the road is difficult, but followed by others, there will never be opportunities, and he enjoyed the joy of success on the road.
"I think Jiayi Pharmaceuticals will be one notch higher than Dongying Pharmaceuticals in the future."
" Dongying Pharmaceuticals is Huang Lequn ten years ago returned home to set up the first successful enterprise.
1991, Huang Lequn entered Bayer's Center for American Studies as a senior researcher.
when he left Bayer in 2005, he was already the chief scientist at the top of the multinational pharmaceutical industry."
years before he returned home, Huang Lequn often traveled between China and the United States to lecture.
's alma mater Nanjing University set up a institute of pharmaceutical chemistry, asked him to come back as director, but used to the superior environment of the United States, Huang Lequn belatedly determined, until 2004, Nanjing University leaders and Huang Lequn in a knee-jerk talk, "We can not give you a high income in the United States, but can give you the mechanism of industrialization of scientific and technological achievements."
" touched Huang Lequn, China has changed, is in the fast lane of rapid development.
Huang Lequn returned to China at the behour of Nanjing University, where he served as vice dean of Nanjing University School of Medicine, professor and director of Nanjing University, where he devoted himself to education and started the East Anglian Pharmaceuticals.
Huang Lequn's initial business model is the first imitation, imitation in China does not have domestic drugs listed imported drugs, to meet the needs of ordinary Chinese people can afford low-cost good medicine.
" on the choice of varieties, some sea return will do a class of new drugs, I judged that China does not have a new class of drugs in the general environment, so I do have independent intellectual property rights of high-end generic drugs.
" East British Pharmaceuticals two fist products: one is injectable anesthetics, changed the original drug must be refrigerated transport conditions, and do not need to go through liver and kidney metabolism, no side effects, the cost of 15% of imported drugs, this chemical species in 2016 sold 2 billion;
2013, Shanghai Pharmaceutical Group acquired a majority stake in Dongying Pharmaceuticals for more than 700 million yuan in a strategic restructuring, and Huang Lequn continued to be chairman of the board of directors to co-ordinate the company's research and development strategy.
with the addition of the sales team of Shanghai Pharmaceutical Group, sales of Dongying Pharmaceuticals doubled.
" scientists in China to do pharmaceutical companies are particularly difficult, new drug development is good, meet GMP is a challenge, because that set of new drugs with the research ideas are completely different, not to mention to face the sale of this completely not good at things, the difficulty inside is not a word or two can be said clearly.
, who started his business at the age of 50, experienced unprecedented hardships and pleasures in the process of developing products from research and development to market and eventually having a place in the market.
20 years from now, there is a Pfizer "uncertainty about its current policy, but the State Drug Administration's attitude is still progressive."
, for example, in China, where imported ginseng preparations cannot be legally purchased, they have introduced a new one-time import policy.
people have no experience, are working hard, this is also the way.
" Huang Lequn believes that a series of reform policies show the determination of the country, at the same time, relatively rigorous and standardized research and development-oriented enterprises are also a great benefit, "we used to do a drug to compete with a hundred enterprises, no matter how much effort and very hard work, as long as the approval down, dozens of all enjoy the same rights and interests, inevitably have murky water fish."
now, can not pass the elimination, under very much effort will get a very good return.
, the former is sales for the king, the future is the variety for the king.
" policy to encourage innovation, enterprises are increasingly international vision, have to go abroad to pilot or introduce talent.
research and development companies like Hengrui are increasingly investing in innovation, and there are more and more investment funds bullish on the pharmaceutical industry, all of which are favorable conditions for China's transition from generics to innovative drugs.
Huang Believes that China's future must be innovation-oriented, but from now on, it may take two decades to reach the level of research and development of new drugs in Europe and the United States.
" innovative drugs must have been made by Pfizer's big drug companies at this level, they invested more than $1 billion to develop a real innovative drug, the market to make a profit and then put into the development of the next new drug, enterprises can not achieve this virtuous cycle without this volume.
" Huang Lequn said, "the whole of China's pharmaceutical companies add up to the size of a large pharmaceutical factory in Europe and the United States, which is a gap, but China may have a Pfizer in two decades."
is it difficult to develop innovative drugs? In Huang Lequn's view, it is not difficult to find compounds, investment is not big, but after the real investment to find compounds began, that is, the so-called "Europe and the United States a new drug more than 1 billion dollars" investment in clinical trials, and, not all compounds will be successful in the development, if the development of five compounds have three is a failure, on average, a drug will cost billions of dollars.
" countries put a lot of money into research institutes and universities, like the atomic bomb, this 'national system' can only find some new drug seedlings.
chinese companies have no way to invest billions in a drug.
" Huang Lequn believes that, in addition to the problem of money there are people's problems, "some of the chairman suddenly want to build a research institute, overseas to find dozens of sea returns, after two years of regret, and all drove away."
such a decision-maker enterprise can make a new drug? Leaders with an international perspective plus a large enough number of companies to become Pfizer.
", although China's environment has not yet provided mature soil for innovative drugs.
but making real innovative drugs is the dream of all drugmakers, and there will be countless failures in the process, but China will eventually have to be innovative.
"